Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease : Final Results From the International Compassionate Use Program

Show full item record



Permalink

http://hdl.handle.net/10138/168552

Citation

Corbacioglu , S , Carreras , E , Mohty , M , Pagliuca , A , Boelens , J J , Damaj , G , Iacobelli , M , Niederwieser , D , Olavarria , E , Suarez , F , Ruutu , T , Verdonck , L , Hume , R , Nejadnik , B , Lai , C , Finetto , G & Richardson , P 2016 , ' Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease : Final Results From the International Compassionate Use Program ' Biology of Blood and Marrow Transplantation , vol. 22 , no. 10 , pp. 1874-1882 . DOI: 10.1016/j.bbmt.2016.07.001

Title: Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease : Final Results From the International Compassionate Use Program
Author: Corbacioglu, Selim; Carreras, Enric; Mohty, Mohamad; Pagliuca, Antonio; Boelens, Jaap Jan; Damaj, Gandhi; Iacobelli, Massimo; Niederwieser, Dietger; Olavarria, Eduardo; Suarez, Felipe; Ruutu, Tapani; Verdonck, Leo; Hume, Robin; Nejadnik, Bijan; Lai, Chinglin; Finetto, Giorgia; Richardson, Paul
Contributor: University of Helsinki, Department of Medicine
Date: 2016-10
Language: eng
Number of pages: 9
Belongs to series: Biology of Blood and Marrow Transplantation
ISSN: 1083-8791
URI: http://hdl.handle.net/10138/168552
Abstract: Hepatic veno-occlusive disease, also called sinusoidal obstruction syndrome (VOD/SOS), is an unpredictable and potentially fatal complication of hematopoietic cell transplantation (HCT) or nontransplantation-associated chemotherapy/radiotherapy. In cases of severe hepatic VOD/SOS, typically defined by associated multiorgan failure (MOF, also known as multiorgan dysfunction), mortality exceeds 80%. Preclinical and early clinical data have provided a rationale for defibrotide treatment in hepatic VOD/SOS. Based on this evidence and in recognition of the dismal prognosis for these patients, defibrotide was made available through an international multicenter compassionate-use program conducted from December 1998 to March 2009. Physicians participating in the program voluntarily provided demographic and outcome data for patients given defibrotide. Efficacy and safety analyses were performed using the data received for 710 treated patients. Defibrotide was given at 10, 25, 40, 60, or 80 mg/kg/day for a median of 15 days (range, 1 to 119 days). By Kaplan-Meier analysis, the estimated overall day +100 survival was 54% (58% in the 25 mg/kg/day dose group). Adverse events (AEs) were reported in 53% of patients. The most common AEs were MOF, progression of hepatic VOD/SOS, sepsis, and graft-versus-host disease, which were consistent with the AEs expected for this patient population. No clinically meaningful trends in AEs were identified by gender, age, or dose group. Safety and efficacy results were consistent with prior studies of defibrotide in hepatic VOD/SOS, and subgroup analyses lend support to the use of the 25 mg/kg/day dose. (C) 2016 American Society for Blood and Marrow Transplantation.
Subject: Defibrotide
Compassionate-use program
Stem cell transplantation
Hepatic veno-occlusive disease
Sinusoidal obstruction syndrome
STEM-CELL TRANSPLANTATION
BONE-MARROW-TRANSPLANTATION
HIGH-RISK POPULATION
SIGNIFICANT TOXICITY
MULTIORGAN FAILURE
ENDOTHELIAL-CELLS
LIVER
THROMBOMODULIN
COMPLICATIONS
PHASE-3
3122 Cancers
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1083879116302099_main.pdf 486.9Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record